What's in Georg Kägi, MD's pipeline?

Georg Kägi, MD has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Georg Kägi, MD's portfolio?

Top competitors by shared drug class: Bayer, EpiCept Corporation, Express Specialty Pharmacy, Grünenthal GmbH, Henry Ford Health System.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/georg-k-gi-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Georg Kägi, MD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Georg Kägi, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 1 shared drug class
EpiCept Corporation · 1 shared drug class
Express Specialty Pharmacy · 1 shared drug class
Grünenthal GmbH · 1 shared drug class
Henry Ford Health System · 1 shared drug class
Johnson & Johnson Consumer and Personal Products Worldwide · 1 shared drug class
NeurogesX · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Georg Kägi, MD:

Cite this brief

Drug Landscape (2026). Georg Kägi, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/georg-k-gi-md. Accessed 2026-06-09.